CoChat
Sign Up
Cited by 102

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer

Noh, Ji Heon, Chang, Young Gyoon, Kim, Min Gyu, Jung, Kwang Hwa, Kim, Jeong Kyu, Bae, Hyun Jin, Eun, Jung Woo, Shen, Qingyu, Kim, Seung-Jin, Kwon, So Hee, Park, Won Sang, Lee, Jung Young, Nam, Suk Woo·2013·Cancer Letters
DOI 10.1016/j.canlet.2013.03.003
Open this paper in CoChat — free account

Abstract

Aberrant regulation of histone deacetylase 2 (HDAC2) plays a pivotal role in the development of hepatocellular carcinoma (HCC), but, the underlying mechanism leading to HDAC2 overexpression is not well understood. We performed microRNA (miRNA) profiling analysis in a subset of HCCs, and identified four down-regulated miRNAs that may target HDAC2 in HCC. Ectopic expression of miRNA mimics evidenced that miR-145 suppresses HDAC2 expression in HCC cells. This treatment repressed cancer cell growth and recapitulated HDAC2 knockdown effects on HCC cells. In conclusion, we suggest that loss or suppression of miR-145 may cause aberrant overexpression of HDAC2 and promote HCC tumorigenesis.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2013.03.003

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 27

  1. Ropero, 2007, The role of histone deacetylases (HDACs) in human cancer, Mol. Oncol., 19, 10.1016/j.molonc.2007.01.001 · DOI
  2. Yang, 2007, HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention, Oncogene, 5310, 10.1038/sj.onc.1210599 · DOI · Paper page
  3. Batty, 2009, Histone deacetylase inhibitors as anti-neoplastic agents, Cancer Lett., 192, 10.1016/j.canlet.2009.03.013 · DOI
  4. Fernandes, 2003, Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms, Mol. Cell, 139, 10.1016/S1097-2765(03)00014-5 · DOI
  5. Zhang, 1999, Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation, Genes Dev., 13, 1924, 10.1101/gad.13.15.1924 · DOI · Paper page
  6. Zhu, 2004, Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis, Cancer Cell, 455, 10.1016/S1535-6108(04)00114-X · DOI
  7. Song, 2005, Increased expression of histone deacetylase 2 is found in human gastric cancer, APMIS, 264, 10.1111/j.1600-0463.2005.apm_04.x · DOI
  8. Noh, 2006, Increased expression of histone deacetylase 2 is found in human hepatocellular carconoma, Mol. Cell. Toxicol., 166
  9. Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  10. Meng, 2007, MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer, Gastroenterology, 647, 10.1053/j.gastro.2007.05.022 · DOI · Paper page
  11. Xiong, 2010, Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma, Hepatology, 836, 10.1002/hep.23380 · DOI
  12. Pineau, 2010, MiR-221 overexpression contributes to liver tumorigenesis, Proc. Natl. Acad. Sci. USA, 107, 264, 10.1073/pnas.0907904107 · DOI
  13. Garofalo, 2011, MicroRNAs: master regulators as potential therapeutics in cancer, Annu. Rev. Pharmacol. Toxicol., 25, 10.1146/annurev-pharmtox-010510-100517 · DOI
  14. Noh, 2011, Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins, PLoS One, e28103, 10.1371/journal.pone.0028103 · DOI
  15. Thiagalingam, 2003, Histone deacetylases: unique players in shaping the epigenetic histone code, Ann. N.Y. Acad. Sci., 84, 10.1111/j.1749-6632.2003.tb05964.x · DOI
  16. Marks, 2001, Histone deacetylases and cancer: causes and therapies, Nat. Rev. Cancer, 194, 10.1038/35106079 · DOI · Paper page
  17. Garzon, 2010, Targeting microRNAs in cancer: rationale, strategies and challenges, Nat. Rev. Drug Discovery, 775, 10.1038/nrd3179 · DOI
  18. Sempere, 2007, Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer, Cancer Res., 11612, 10.1158/0008-5472.CAN-07-5019 · DOI
  19. Iorio, 2005, MicroRNA gene expression deregulation in human breast cancer, Cancer Res., 7065, 10.1158/0008-5472.CAN-05-1783 · DOI · Paper page
  20. Schepeler, 2008, Diagnostic and prognostic microRNAs in stage II colon cancer, Cancer Res., 68, 6416, 10.1158/0008-5472.CAN-07-6110 · DOI
  21. Sachdeva, 2009, P53 represses c-Myc through induction of the tumor suppressor miR-145, Proc. Natl. Acad. Sci., 3207, 10.1073/pnas.0808042106 · DOI
  22. Shi, 2007, MicroRNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells, J. Biol. Chem., 282, 32582, 10.1074/jbc.M702806200 · DOI
  23. Sachdeva, 2010, MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1, Cancer Res., 378, 10.1158/0008-5472.CAN-09-2021 · DOI
  24. Xu, 2012, MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis, Nucl. Acids Res., 761, 10.1093/nar/gkr730 · DOI
  25. Yang, 2011, MicroRNA-145 regulates chondrogenic differentiation of mesenchymal stem cells by targeting Sox9, PLoS One, e21679, 10.1371/journal.pone.0021679 · DOI
  26. Varnholt, 2008, MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma, Hepatology, 47, 1223, 10.1002/hep.22158 · DOI
  27. Gao, 2011, Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis, J. Hepatol., 1177, 10.1016/j.jhep.2010.09.023 · DOI

Cited by

Sorted by citations

See all 102

Metadata

Authors
Noh, J. H., Chang, Y. G., Kim, M. G., Jung, K. H., Kim, J. K., Bae, H. J., Eun, J. W., Shen, Q., Kim, S.-J., Kwon, S. H., Park, W. S., Lee, J. Y., & Nam, S. W.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2013-07
Volume
335
Issue
2
Pages
455-462
ISSN
0304-3835
DOI
10.1016/j.canlet.2013.03.003
Cited by
102
References
2
Language
en
Licence
Funders
  • Ministry of Education, Science and Technology (2011-0010705, 2012M3A9D1054476)
  • Catholic University of Korea
  • National Research Foundation of Korea
  • Korea Science and Engineering Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review